Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Provided By GlobeNewswire
Last update: Jan 14, 2025
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers
Trial marks key milestone in driving pipeline progress
Read more at globenewswire.com
